MG
VIRX

Michael Gelband’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Michael Gelband’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28,948
Closed -$138K – 2567
2022
Q1 		$138K Buy
+28,948
New +$87.2K ﹤0.01% 1969
2021
Q2 		– Sell
-60,443
Closed -$559K – 2911
2021
Q1 		$559K Buy
+60,443
New +$630K 0.01% 1268
2020
Q1 		– Sell
-423
Closed -$5K – 1745
2019
Q4 		$5K Buy
+423
New +$7.08K ﹤0.01% 1480

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Michael Gelband's VIRX Position: Q2 2022 in Review

Michael Gelband sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 28,948 shares — an estimated $138K sold.

Michael Gelband first reported a position in VIRX in Q4 2019 and held it in 3 quarters. The position peaked at $559K in Q1 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Michael Gelband reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 28,948 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $138K.
  • Michael Gelband first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Michael Gelband's Viracta Therapeutics, Inc. Common Stock position peaked at $559K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.